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we calculated Pearson correlations between changes in KCCQ and Peak VO2 at 3 
and 12 months. Conﬁdence intervals of r’s were estimated via bootstrapping. 
RESULTS: The SIMPLE method produced a wider distribution of change scores 
than the other two methods. However, compared to BLUP-1 and BLUP-2, the 
SIMPLE method estimated lower correlations between changes in KCCQ and Peak 
VO2 at both 3 and 12 months: At 3 months, SIMPLE r (95% CI) = .16 (.11, .21), 
BLUP-1 r = .28 (.18, .38), and BLUP-2 r = .29 (.22, .40). At 12 months, SIMPLE 
r = .22 (.15, .27), BLUP-1 r = .27 (.21, .33), and BLUP-2 r = .31 (.25, .40). CON-
CLUSIONS: Compared to the SIMPLE approach, the BLUP approach has the fol-
lowing advantages: 1) uses all of the longitudinal data available; 2) estimates with 
reasonable assumptions about missing data; 3) accommodates nonlinear and differing 
longitudinal trajectories for the PRO and clinical measures; and 4) minimizes the 
inﬂuence of noisy data.
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OBJECTIVES: The aim was to measure the effects on symptoms of a direct current 
cardioversion (DC) in patients with atrial ﬁbrillation (AF) with a new, short, validated 
AF-speciﬁc questionnaire, the AF6. METHODS: One hundred and eleven patients (89 
men, 22 women) were included in the study. Their symptoms were screened before 
and 12 ± 3 days after DC, using AF6, consisting of 6 items, representing the most 
common symptoms or experiences of patients in an AF clinic. Symptom scores were 
analyzed in the whole study population as well as in clinical responders and non-
responders, using sinus rhythm (SR) at follow-up as a clinical anchor. RESULTS: The 
total mean score in the study population decreased, (18 ± 12.4 to 13 ± 11.6, p < 
0.0001), and in responders (n = 56), (22 ± 14 vs. 12 ± 12, p < 0.01), but not in non-
responders (n = 55), 14 ± 9 vs. 14 ± 11, N.S. The highest scoring items were ´breathing 
difﬁculties upon exertion´ and ´tiredness due to atrial ﬁbrillation´, and they were also 
the most frequently scoring items (80% and 83%, respectively). The other items of 
the scale were present in 65%, 64%, 48% and 36% of the patients. ´Worry/anxiety 
due to atrial ﬁbrillation´ was present in 48% of the patients, scoring high when 
present. ´Breathing difﬁculties at rest´ was the least and the lowest scoring item. Effect 
sizes ranged from 0 to 0.52, in responders from 0.10 to 0.85, and in non-responders 
from −0.23 to 0.34, the highest scores consistently relating to ´tiredness due to atrial 
ﬁbrillation. CONCLUSIONS: AF6 demonstrated adequate responsiveness to change, 
and effect sizes were mostly moderate, in responders moderate to high. The symptom 
scores measured by AF6 decreased signiﬁcantly after DC cardioversion, especially in 
responders in terms of SR, conﬁrming, that SR is an important clinical anchor.
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OBJECTIVES: Stroke is the second leading cause of death worldwide and a major 
cause of long-term disability. Increasingly, stroke outcomes research is following clini-
cal practice and not only considers all strokes together but divides them into various 
risk-proﬁle subtypes. Following this approach, we performed a population-based 
study of all residents of Erlangen, Bavaria, Germany, to determine the risk proﬁle 
distributions in a well-deﬁned population and their long-term impact on disability and 
patterns of care. METHODS: Since 2000 the Erlangen Stroke Project (ESPro) is the 
reporting centre for stroke for the German Federal Government. As the only popula-
tion-based stroke registry in Germany ESPro is recording each patient living in Erlan-
gen, Bavaria, Germany (source population 100,500) who suffered from stroke. The 
patients were analysed at time points after admission as well as 3 and 12 month after 
the event. A total of 1355 patients with a ﬁrst-stroke were registered in the ESPro. 
The cause of ischemic stroke was classiﬁed according to the TOAST criteria. Etiologi-
cal TOAST classiﬁcation was performed in 89% (1206) of ischemic strokes. RESULTS: 
The etiological classiﬁcation of brain infarctions resulted in 12% large-artery athero-
sclerosis, 26% cardioembolism, 24% small-artery occlusion, 37% strokes of undeter-
mined etiology and 2% strokes of other determined etiology. While 20% of the 
patients were independent functionally at the Barthel index at admission, the number 
was 39% after 12 month. The category large-artery atherosclerosis showed the stron-
gest relationship with the occurring need of care. The OR with very strong care needs 
12.79 (95% CI3.71 –44.07) lay particularly high in comparison with an OR of 6.95 
(95% CI 2.16–22.33) in the category cardioembolism. CONCLUSIONS: The TOAST 
classiﬁcation provides an appropriate tool for estimating the need of care. In particular 
the patients in the TOAST category large-artery atherosclerosis showed a high level 
of a need of care at the long-term follow-up.
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OBJECTIVES: Recent studies have found that the use of psychotropic medications in 
women with coronary artery disease (CAD) led to long-term adverse outcomes such 
as cardiovascular adverse events. This study examined the effect of psychotropic 
medication use on the health-related quality of life (HRQoL) of women with CAD. 
METHODS: Analysis was conducted using the 2007 Medical and Expenditure Panel 
Survey (MEPS) database, which is nationally representative of the US civilian non-
institutionalized population. Female patients >= 18 years with CAD were included in 
this analysis. CAD patients were identiﬁed using a combination of International Clas-
siﬁcation of Diseases (ICD-9) diagnosis codes. HRQoL was measured using the Physi-
cal Component Summary (PCS-12) and Mental Component Summary (MCS-12) of 
the Short-Form 12 Version 2 (SF-12). HRQoL and sociodemographic characteristics 
of female CAD patients who used at least one psychotropic medication were compared 
with those who did not use any psychotropic medications. Bivariate comparisons were 
made using t-tests for continuous variables and chi-square tests for categorical vari-
ables. Multivariate comparisons using analysis of covariance (ANCOVA) models were 
conducted to assess the association of HRQoL with psychotropic use after adjusting 
for age, race, education, marital status, insurance status, and the number of medical 
conditions in 2007. RESULTS: Of the 4,253,569 women with CAD in the US, 
1,312,413 (30.9%) took psychotropic medications. Women taking psychotropic medi-
cations reported a signiﬁcantly higher number of medical conditions compared to 
non-users (13.25 vs. 9.51, p < 0.0001). The mean unadjusted differences in PCS-12 
and MCS-12 scores between psychotropic drug users versus non-users suggested worse 
scores among women taking psychotropic medications (PCS-12: −4.93; p = 0.03 and 
MCS-12: −9.46; p = 0.0006), and this trend in differences continued after adjusting 
for covariates (PCS-12: −2.23; p = 0.26 and MCS-12: −7.51; p = 0.0034). CONCLU-
SIONS: Consistent with ﬁndings of long-term adverse outcomes from previous studies, 
psychotropic medication use among women with CAD was associated with signiﬁ-
cantly worse HRQoL.
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OBJECTIVES: To review studies assessing the quality of life associated with thoracic 
aortic diseases (TADs) and their treatment with Open Aortic Repair (OAR), Thoracic 
Endovascular Aortic Repair (TEVAR) or medical management (MM). METHODS: 
PubMed and EMBASE were searched covering terms related to TADs and patient 
reported outcomes/quality of life. The search was limited to articles in English and to 
studies relating to humans. However, no time period was speciﬁed so as to enable a 
broad search. The studies obtained were analysed qualitatively. RESULTS: Eight 
studies met the review criteria. Published 1998 and 2009, four dealt with aneurysms, 
two with dissections and two with more than one of the TADs; all of them were based 
on assesment of quality of life after treatment rather than on the disease itself. Only 
one study covered emergency versus elective surgery. The number of patients was very 
small in all studies, ranging from 75 to 11. Mean follow-up varied from 7 to 76 
months. The most commonly used instrument was the SF-36. Two studies also used 
the Hospital Anxiety and Depression Score (HADS) in addition to the SF-36. One 
study adopted the SWEDQUAL questionnaire ; another study had recourse to the 
Illness Intrusiveness Rating Scale (IIRS) and the Karnofsky Activity Scale (KAS), which 
lacked information on proper validation for this target population. All in all, none of 
the study conducted the quality of life assessment appropriately, particularly with 
regard to the follow-up period, the lack of pre-operative assessment and lack of direct 
comparison between interventions. Lastly, there were no utility assessments to be 
found, which would be essential to arrive at QALY values and thus take the process 
of economic analysis forward. CONCLUSIONS: The studies available so far do not 
provide evidence of the quality of life associated with TADs, as well as conclusive 
evidence of the quality of life associated with OAR; TEVAR and/or MM.
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OBJECTIVES: Diabetes mellitus has been deﬁned as one of the global epidemics of 
chronic diseases by the World Health Organization. Patients with diabetes are at an 
increased risk of developing macrovascular disease. The purpose of this study was to 
examine the marginal impact of macrovascular comorbidities on health-related quality 
of life (HRQoL) of patients with diabetes in a United States nationally representative 
sample. METHODS: Using the pooled Medical Expenditure Panel Survey (MEPS) 
2001 and 2003 data, a nationally representative adult sample (age ≥18) was included 
in the study. The HRQoL outcomes included the SF-12 physical component summary 
(PCS) score, SF-12 mental component summary (MCS) score, EQ-5D preference-based 
index score, and visual analog scale (VAS). Ordinary least square regressions were 
used to identify the relationship between macrovascular disease conditions and PCS 
(and MCS) after controlling for age, sex, race, ethnicity, education, income, smoking 
status, health insurance, proxy response, and number of other comorbid categories. 
Due to the distributions of the EQ-5D preference-based index and VAS score, censored 
linear deviations estimator (CLAD) regressions were employed. All statistics were 
adjusted using the proper sampling weight from the MEPS. RESULTS: The average 
PCS, MCS, EQ-5D index, and VAS scores for patients with diabetes were 40.5, 48.5, 
0.75, and 66.6, respectively for the sample. Compared to diabetes patients without 
macrovascular comorbidities (N = 2,809), those with macrovascular comorbidities (N 
